c-Met expression in renal cell carcinoma with bone metastases
Hepatocyte growth factor (HGF)/c-Met pathway is implicated in embryogenesis and organ development and differentiation. Germline or somatic mutations, chromosomal rearrangements, gene amplification, and transcriptional upregulation in MET or alterations in autocrine or paracrine c-Met signalling have...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-12-01
|
| Series: | Journal of Bone Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2212137420300701 |
| _version_ | 1819057346064678912 |
|---|---|
| author | Rita Silva Paiva Inês Gomes Sandra Casimiro Isabel Fernandes Luís Costa |
| author_facet | Rita Silva Paiva Inês Gomes Sandra Casimiro Isabel Fernandes Luís Costa |
| author_sort | Rita Silva Paiva |
| collection | DOAJ |
| description | Hepatocyte growth factor (HGF)/c-Met pathway is implicated in embryogenesis and organ development and differentiation. Germline or somatic mutations, chromosomal rearrangements, gene amplification, and transcriptional upregulation in MET or alterations in autocrine or paracrine c-Met signalling have been associated with cancer cell proliferation and survival, including in renal cell carcinoma (RCC), and associated with disease progression. HGF/c-Met pathway has been shown to be particularly relevant in tumors with bone metastases (BMs). However, the efficacy of targeting c-Met in bone metastatic disease, including in RCC, has not been proven. Therefore, further investigation is required focusing the particular role of HGF/c-Met pathway in bone microenvironment (BME) and how to effectively target this pathway in the context of bone metastatic disease. |
| first_indexed | 2024-12-21T13:37:50Z |
| format | Article |
| id | doaj.art-ddd0e07c8ccf4f1c9d1a509d179a1619 |
| institution | Directory Open Access Journal |
| issn | 2212-1374 |
| language | English |
| last_indexed | 2024-12-21T13:37:50Z |
| publishDate | 2020-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Bone Oncology |
| spelling | doaj.art-ddd0e07c8ccf4f1c9d1a509d179a16192022-12-21T19:02:08ZengElsevierJournal of Bone Oncology2212-13742020-12-0125100315c-Met expression in renal cell carcinoma with bone metastasesRita Silva Paiva0Inês Gomes1Sandra Casimiro2Isabel Fernandes3Luís Costa4Oncology Division, Hospital de Santa Maria, CHULN, 1649-035 Lisboa, PortugalInstituto de Medicina Molecular - João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisbon, PortugalInstituto de Medicina Molecular - João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisbon, PortugalOncology Division, Hospital de Santa Maria, CHULN, 1649-035 Lisboa, Portugal; Instituto de Medicina Molecular - João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisbon, PortugalOncology Division, Hospital de Santa Maria, CHULN, 1649-035 Lisboa, Portugal; Instituto de Medicina Molecular - João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisbon, Portugal; Corresponding author at: Oncology Division, Hospital de Santa Maria, 1649-035 Lisbon, Portugal.Hepatocyte growth factor (HGF)/c-Met pathway is implicated in embryogenesis and organ development and differentiation. Germline or somatic mutations, chromosomal rearrangements, gene amplification, and transcriptional upregulation in MET or alterations in autocrine or paracrine c-Met signalling have been associated with cancer cell proliferation and survival, including in renal cell carcinoma (RCC), and associated with disease progression. HGF/c-Met pathway has been shown to be particularly relevant in tumors with bone metastases (BMs). However, the efficacy of targeting c-Met in bone metastatic disease, including in RCC, has not been proven. Therefore, further investigation is required focusing the particular role of HGF/c-Met pathway in bone microenvironment (BME) and how to effectively target this pathway in the context of bone metastatic disease.http://www.sciencedirect.com/science/article/pii/S2212137420300701Bone metastasesKidney cancerHGF/c-MetTargeted therapy |
| spellingShingle | Rita Silva Paiva Inês Gomes Sandra Casimiro Isabel Fernandes Luís Costa c-Met expression in renal cell carcinoma with bone metastases Journal of Bone Oncology Bone metastases Kidney cancer HGF/c-Met Targeted therapy |
| title | c-Met expression in renal cell carcinoma with bone metastases |
| title_full | c-Met expression in renal cell carcinoma with bone metastases |
| title_fullStr | c-Met expression in renal cell carcinoma with bone metastases |
| title_full_unstemmed | c-Met expression in renal cell carcinoma with bone metastases |
| title_short | c-Met expression in renal cell carcinoma with bone metastases |
| title_sort | c met expression in renal cell carcinoma with bone metastases |
| topic | Bone metastases Kidney cancer HGF/c-Met Targeted therapy |
| url | http://www.sciencedirect.com/science/article/pii/S2212137420300701 |
| work_keys_str_mv | AT ritasilvapaiva cmetexpressioninrenalcellcarcinomawithbonemetastases AT inesgomes cmetexpressioninrenalcellcarcinomawithbonemetastases AT sandracasimiro cmetexpressioninrenalcellcarcinomawithbonemetastases AT isabelfernandes cmetexpressioninrenalcellcarcinomawithbonemetastases AT luiscosta cmetexpressioninrenalcellcarcinomawithbonemetastases |